Itraconazole in treatment of mCRPC: an update

Posted on April 9, 2012 by Sitemaster

Researchers at Johns Hopkins have, for a while, been investigating the potential of the antifungal agent itraconazole as a treatment for men with metastatic, castration-resistant prostate cancer (mCRPC). We last reported on this research nearly a year ago, based on a presentation at the annual meeting of the American Society of Clinical Oncology (ASCO) in [...]

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: , , , | 1 Comment »

Aflibercept fails to extend survival of men with mCRPC in pivotal Phase III trial

Posted on April 6, 2012 by Sitemaster

Not entirely surprisingly, in a joint media release from Regeneron Pharmaceuticals and Sanofi issued yesterday, the two companies have announced that the investigational agent aflibercept did not extend overall survival in combination with docetaxel and prednisone in the randomized Phase III VENICE trial.

Filed under: Drugs in development | Tagged: , , , , , | Leave a Comment »

Baseline serum androgen levels key to clinical responses to abiraterone acetate and prednisone

Posted on April 5, 2012 by Sitemaster

A retrospective evaluation of data from the multinational Phase III clinical trial of abiraterone has suggested that a subset of the patients in the trial  had significantly better clinical responses than others.

Filed under: Drugs in development, Management, Treatment | 2 Comments »

MDV3100 gets a proper scientific name

Posted on April 4, 2012 by Sitemaster

According to a media release issued by Medivation immediately prior to the annual meeting of the American Association for Cancer Research in Chicago (now wrapping up), the drug we have all known as MDV3100 for the past few years now has an approved “scientific” name: enzalutamide.

Filed under: Drugs in development | Tagged: , , | 1 Comment »

SU2C and PCF fund $10 million research study into why / how new drugs work in mCRPC

Posted on April 2, 2012 by Sitemaster

Researchers at a consortium of seven major cancer centers have been awarded a $10 million, 3-year grant to continue explorations into the individualization of treatment for men with advanced and metastatic forms of prostate cancer. The grant is funded in a collaboration between Stand Up To Cancer (SU2C) and the Prostate Cancer Foundation (PCF).

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: , , , , | Leave a Comment »

Tokai to move TOK-001 (galeterone) into Phase II trials later in year

Posted on April 1, 2012 by Sitemaster

According to a media release issued on Saturday by Tokai Pharmaceuticals, their investigational agent galeterone (TOK-001) “was well-tolerated with minimal side effects and demonstrated efficacy” in a Phase I clinical trial among men with metastatic, castration-resistant prostate cancer (mCRPC).

Filed under: Drugs in development | Tagged: , , , , | Leave a Comment »

Another step in the projected marketing battle: abiraterone vs. MDV3100

Posted on March 23, 2012 by Sitemaster

We have become aware of what appears to be the next step in the projected marketing battle between MDV3100 and abiraterone acetate for prominence as the “better” form of androgen suppressive agent in men with metastatic, castration-resistant prostate cancer (mCRPC).

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: , , , | 8 Comments »

Newly identified mechanism may affect or control progression of metastatic prostate cancer

Posted on March 22, 2012 by Sitemaster

According to a media release issued today by the American Association for Cancer Reasearch, a paper just published in Cancer Discovery has suggested that a gene known as PFKFB4 may be implicated in the more aggressive growth of metastatic prostate cancer cells.

Filed under: Drugs in development | Tagged: , , , , | 1 Comment »

It’s time to badger your Congressman/Congresswoman again …

Posted on March 13, 2012 by Sitemaster

As the annual Defense appropriations cycle starts once again, The “New” Prostate Cancer InfoLink encourages all you US-based prostate cancer patients and other US-based voters to e-mail your Congressman or Congresswoman and ask them to support prostate cancer research funding through the “Dear Colleague” letter being circulated by Representative Pete King in the House.

Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Prevention, Risk, Treatment | Tagged: , , , , , | 1 Comment »

Why would anyone develop new drugs if international patent law can just be ignored?

Posted on March 13, 2012 by Sitemaster

There are two ways to look at a ruling issued yesterday by the Indian controller general of patents, designs and trademarks: it can either be seen as a major victory for patients who had no prior hope of treatment with a highly effective anticancer agent because of its cost … or it can be seen [...]

Filed under: Drugs in development | Tagged: , , , , | 7 Comments »

OncoGeneX/Teva halt SATURN trial, start new Phase III study with OGX-011

Posted on March 9, 2012 by Sitemaster

According to a media release from the companies issued yesterday, OncoGeneX and Teva have stopped enrolling patients into the SATURN trial, which was designed to see if OGX-011 (custirsen) could ameliorate bone pain

Filed under: Drugs in development, Management, Treatment | Tagged: , , , , | Leave a Comment »

Abiraterone acetate superior to placebo in chemotherapy-naïve men with mCRPC

Posted on March 8, 2012 by Sitemaster

According to a media release from Janssen Research & Development (a unit of Johnson & Johnson), an independent trial monitoring committee has advised the company to stop the randomized, Phase III clinical trial of abiraterone acetate + predisone compared to a placebo + prednisone in treatment of chemotherapy-naïve patients with metastatic, castration-resistant prostate cancer (mCRPC).

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: , , , , | 5 Comments »

Continuing evolution of opportunities in the management of mCRPC

Posted on March 5, 2012 by Sitemaster

Two media releases today give us additional insights into the future for the management of metastatic castration-resistant forms of prostate cancer (mCRPC) … and perhaps earlier stages of the disease too.

Filed under: Drugs in development, Management, Treatment | Leave a Comment »

Adjuvant degarelix in combination with radiation therapy (instead of an LHRH agonist + an antiandrogen)

Posted on February 27, 2012 by Sitemaster

According to an announcement from the European Association for Urology (EAU) earlier today, data from a recently completed trial demonstrate that degarelix is “non-inferior” to the LHRH agonist goserelin acetate + the antiandrogen bicalutamide at reducing prostate volume in men with advanced hormone- dependent prostate cancer.

Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: , , , | 2 Comments »

Small, Phase I combo trial suggests 3-year overall survival in men with mCRPC

Posted on February 23, 2012 by Sitemaster

A media release issued earlier today by Barvarian Nordic (the developer of Prostvac®) gives us an inkling of where we may be headed in the development of combination therapies for the management of late stage (and maybe even earlier stage) forms of prostate cancer.

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: , , , , , , , | Leave a Comment »

« Previous Page — Next Page »
Follow

Get every new post delivered to your Inbox.

Join 325 other followers